NCT00110396View on ClinicalTrials.gov

Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis

PHASE3CompletedINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

April 30, 2007

Study Completion Date

April 30, 2007

Conditions
Multiple Sclerosis
Interventions
BIOLOGICAL

Interferon-beta-1a FBS-free/HSA-free

Pre-filled syringes 44mcg/injected subcutaneous 3x per week. Total study period is 96 weeks.

Trial Locations (1)

02370

Local US Medical Information, Rockland

Sponsors

Lead Sponsor

EMD Serono

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

EMD Serono

INDUSTRY